Jeff Evans has been editor of Rheumatology News/MDedge Rheumatology and the EULAR Congress News since 2013. He started at Frontline Medical Communications in 2001 and was a reporter for 8 years before serving as editor of Clinical Neurology News and World Neurology, and briefly as editor of GI & Hepatology News. He graduated cum laude from Cornell University (New York) with a BA in biological sciences, concentrating in neurobiology and behavior.
News
Model may predict prolonged status epilepticus outcomes
- Author:
- Jeff Evans
The two-variable model must now undergo external validation.
News
ACR forges ahead with physician-focused APM for RA
- Author:
- Jeff Evans
CHICAGO – A work group is determining cost and payment details through surveys and a financial analysis of two large practices.
News
Funding for NIH BRAIN Initiative reaches new heights
- Author:
- Jeff Evans
The NIH announced more than $220 million in additional funding for BRAIN Initiative research projects in 2018....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2017/Worthing_Angus_DC_web.jpg)
Bills affecting rheumatologists make way to Capitol Hill
- Author:
- Jeff Evans
CHICAGO – Congressional bills have been introduced that seek exceptions for “fail first” insurer policies,...
News
3-D model neurovascular unit developed with working blood-brain barrier
- Author:
- Jeff Evans
The model could have potential applications in drug discovery, toxicity screening, and disease modeling.
News
Studies reveal pregnancy trends in American women with MS
- Author:
- Jeff Evans
Women with MS are older at pregnancy and have more complications than do women without MS, and relatively few...
News
Hot topic explores neuropathologic differences between MS individuals
- Author:
- Jeff Evans
Attendees will hear about the new myelocortical MS subtype and potential biomarkers for differentiating...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/multiple_sclerosis_3_web.jpg)
Benign MS is real in small minority of patients
- Author:
- Jeff Evans
But benign disease tracks poorly with disability measures and lacks agreement between patients and physicians.
News
Noninferiority endpoint not met between Xeljanz formulations for RA
- Author:
- Jeff Evans
Noninferiority of tofacitinib once daily to twice daily was not demonstrated in Japanese patients with RA....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/costs_calculator_web.jpg)
Cost of medical care for older adults with epilepsy steadily grows
- Author:
- Jeff Evans
In the United States, costs during 2003-2014 were nearly twice as high as they were for those without epilepsy.
Audio
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/ms_drugs_in_medicare_part_d_higher_tiers_less_coverage_2962-18_1-00.png)
MS drugs in Medicare Part D: Higher tiers, less coverage, more prior authorizations
- Author:
- Jeff Evans
LOS ANGELES – The 2007-2016 analysis includes 11 drugs falling under Medicare Part D.
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/April-2018/Wechsler_Lawrence_PA_web.jpg)
VIDEO: Meeting stroke screening demand will require systems’ reorganization
- Author:
- Jeff Evans
LOS ANGELES – Telestroke triage of patients by comprehensive stroke centers is the way to go, says Dr. Lawrence Wechsler.
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/April-2018/Callaghan_Brian_MI_web.jpg)
VIDEOS: High-priced drugs, out-of-pocket costs raise challenges for neurologists
- Author:
- Jeff Evans
LOS ANGELES – Members of the AAN Neurology Drug Pricing Task Force spoke about the issues that arise in getting patients access to high-cost drugs...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/April-2018/Sellers_Jessie_TN_web.jpg)
Real-world data so far support pimavanserin trial results
- Author:
- Jeff Evans
LOS ANGELES – Two studies report on clinicians’ experiences with 105 patients.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/brain_blue_web.jpg)
Blood-brain barrier health may signal early loss of MS treatment response
- Author:
- Jeff Evans
A single dynamic contrast-enhanced MRI scan at 6 months was predictive in patients taking natalizumab or fingolimod.